Work Here?
Overview
Encoded Therapeutics develops precision gene therapies for pediatric central nervous system disorders, including Dravet syndrome. Its therapies use a unique targeting and regulation platform to deliver genetic payloads to specific brain cell types based on genetic profiles, increasing gene specificity, cell selectivity, and potency. The company aims to distinguish itself by focusing on cell-type–specific brain targeting and safety in pediatric patients to reduce off-target effects and toxicity compared with earlier gene therapies. Its goal is to bring clinically effective treatments to patients and work with healthcare providers to commercialize these therapies.
About Encoded Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series D
Total Funding
$239.1M
Headquarters
San Francisco, California
Founded
2014
People at Encoded Therapeutics
People at Encoded Therapeutics who can refer or advise you
Simplify's Take
What believers are saying
- 78% median seizure reduction through 7 months with no serious adverse events by December 5, 2025.
- Breakthrough Therapy, Fast Track, and Orphan Drug designations from FDA accelerating regulatory pathway.
- UK, US, and Australia CTA/IND approvals enabling global ENDEAVOR and POLARIS clinical development by 2024.
What critics are saying
- AAV9-induced liver toxicity escalation in pediatric cohort with 40–60% probability within 12–18 months.
- Competitor Stoke Cyclic's SCN1A therapy outpacing clinical enrollment, potentially starving ENDEAVOR trial of participants by Q3 2026.
- ICV injection procedure failure causing permanent ventricular damage with 25–40% probability within 9–12 months.
What makes Encoded Therapeutics unique
- Cell-selective gene therapy targeting GABAergic neurons specifically for Dravet syndrome.
- One-time AAV9 gene regulation therapy upregulating SCN1A expression preferentially in inhibitory neurons.
- Proprietary platform achieving precise brain expression while addressing AAV class toxicity in primates.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$239.1M
Above
Industry Average
Funded Over
3 Rounds
SoftBank
Menlo VenturesIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Parental Leave
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Health Savings Account/Flexible Spending Account
Stock Options
Growth & Insights and Company News
6 month growth
↓ -8%1 year growth
↓ -8%2 year growth
↑ 0%A little over a year ago, Encoded launched its DRAVET ENGAGE initiative to capture the Dravet syndrome patient community’s experiences and perspectives and to solicit feedback on clinical study protocols and designs, as well as on educational materials.
Encoded Therapeutics is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Encoded Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series D
Total Funding
$239.1M
Headquarters
San Francisco, California
Founded
2014
Encoded Therapeutics is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today